Design of a multicentre randomized controlled trial to assess the safety and efficacy of dose titration by specialized nurses in patients with heart failure. ETIFIC study protocol.

dc.contributor.authorOyanguren, Juana
dc.contributor.authorGarcía-Garrido, Lluisa
dc.contributor.authorNebot Margalef, Magdalena
dc.contributor.authorLekuona, Iñaki
dc.contributor.authorComín Colet, Josep
dc.contributor.authorManito Lorite, Nicolás
dc.contributor.authorRoure, Julia
dc.contributor.authorRuiz Rodríguez, Pilar
dc.contributor.authorEnjuanes, Cristina
dc.contributor.authorLatorre, Pedro
dc.contributor.authorTorcal Laguna, Jesús
dc.contributor.authorGarcía-Gutiérrez, Susana
dc.date.accessioned2022-09-22T17:51:31Z
dc.date.available2022-09-22T17:51:31Z
dc.date.issued2017-11-04
dc.date.updated2022-09-22T17:51:32Z
dc.description.abstractHeart failure (HF) is associated with many hospital admissions and relatively high mortality, rates decreasing with administration of beta-blockers (BBs), angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers, and mineralocorticoid receptor antagonists. The effect is dose dependent, suboptimal doses being common in clinical practice. The 2012 European guidelines recommend close monitoring and dose titration by HF nurses. Our main aim is to compare BB doses achieved by patients after 4 months in intervention (HF nurse-managed) and control (cardiologist-managed) groups. Secondary aims include comparing doses of the other aforementioned drugs achieved after 4 months, adverse events, and outcomes at 6 months in the two groups. Methods We have designed a multicentre (20 hospitals) non-inferiority randomized controlled trial, including patients with new-onset HF, left ventricular ejection fraction ≤40%, and New York Heart Association class II-III, with no contraindications to BBs. We will also conduct qualitative analysis to explore potential barriers to and facilitators of dose titration by HF nurses. In the intervention group, HF nurses will implement titration as prescribed by cardiologists, following a protocol. In controls, cardiologists will both prescribe and titrate doses. The study variables are doses of each of the drugs after 4 months relative to the target dose (%), New York Heart Association class, left ventricular ejection fraction, N-terminal pro B-type natriuretic peptide levels, 6 min walk distance, comorbidities, renal function, readmissions, mortality, quality of life, and psychosocial characteristics. Conclusions The trial seeks to assess whether titration by HF nurses of drugs recommended in practice guidelines is safe and not inferior to direct management by cardiologists. The results could have an impact on clinical practice.
dc.format.extent13 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec702616
dc.identifier.issn2055-5822
dc.identifier.urihttps://hdl.handle.net/2445/189275
dc.language.isoeng
dc.publisherJohn Wiley & Sons
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1002/ehf2.12152
dc.relation.ispartofESC Heart Failure, 2017, vol. 4, num. 4, p. 507-519
dc.relation.urihttps://doi.org/10.1002/ehf2.12152
dc.rightscc-by-nc-nd (c) Oyanguren, Juana et al., 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceArticles publicats en revistes (Ciències Clíniques)
dc.subject.classificationInsuficiència cardíaca
dc.subject.classificationInfermeria
dc.subject.classificationUrgències mèdiques
dc.subject.otherHeart failure
dc.subject.otherNursing
dc.subject.otherMedical emergencies
dc.titleDesign of a multicentre randomized controlled trial to assess the safety and efficacy of dose titration by specialized nurses in patients with heart failure. ETIFIC study protocol.
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
702616.pdf
Mida:
4.32 MB
Format:
Adobe Portable Document Format